Trial Profile

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Canagliflozin (Primary)
Indications Diabetic nephropathies; Heart failure; Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Focus Pharmacokinetics

Most Recent Events

04 Sep 2019 Status changed from recruiting to completed.
15 May 2019 Planned End Date changed from 1 May 2019 to 1 May 2020.
15 May 2019 Planned primary completion date changed from 1 May 2019 to 1 May 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com